SLC5A2 and type 2 diabetes mellitus: The sodium glucose transporter 2 (SGLT2) inhibitor empagliflozin also showed positive effects on non-invasive measures of MASLD and liver fibrosis in humans without T2DM, while its molecular mechanisms promoting liver health are still not elucidated [19].